INOVIO Interview Guide

Inovio Pharmaceuticals is at the forefront of revolutionizing vaccine delivery through its innovative electroporation infusion therapy, which utilizes electrical pulses to enhance the permeability of cell membranes, thereby optimizing the administration of its pioneering DNA vaccines. These vaccines are designed to combat not only various cancers but also chronic infectious diseases like HIV and hepatitis C. Inovio's cutting-edge SynCon technology aims to identify common traits among different viral strains to create a universal flu vaccine, a significant advancement over traditional, strain-specific flu vaccines. The company also has a robust pipeline that includes anti-inflammatory drugs and DNA-based growth hormones for livestock, positioning it as a key player in the biotech and pharmaceuticals industry. With a team size of 201 to 500, Inovio is dedicated to transforming healthcare through science and technology.